IRIS PubliCatt

Rossetti, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.216
EU - Europa 1.038
AS - Asia 473
AF - Africa 26
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 2.772
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.181
IT - Italia 210
SE - Svezia 202
SG - Singapore 154
CN - Cina 151
FR - Francia 142
PL - Polonia 113
DE - Germania 87
IN - India 67
IE - Irlanda 62
GB - Regno Unito 46
ID - Indonesia 44
FI - Finlandia 37
RU - Federazione Russa 26
ES - Italia 25
UA - Ucraina 24
CA - Canada 18
MX - Messico 15
BE - Belgio 13
PT - Portogallo 11
HK - Hong Kong 10
KR - Corea 10
PH - Filippine 10
CM - Camerun 8
LT - Lituania 8
IR - Iran 7
RO - Romania 7
ZA - Sudafrica 7
NL - Olanda 6
GR - Grecia 5
TR - Turchia 5
TW - Taiwan 5
CI - Costa d'Avorio 4
CO - Colombia 4
EU - Europa 4
AU - Australia 3
CH - Svizzera 3
CL - Cile 3
UG - Uganda 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
BR - Brasile 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
JP - Giappone 2
TH - Thailandia 2
AR - Argentina 1
BG - Bulgaria 1
EC - Ecuador 1
HN - Honduras 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MK - Macedonia 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
TN - Tunisia 1
VN - Vietnam 1
Totale 2.772
Salva come PNG Salva come JPEG
Città #
Chandler 320
Singapore 112
Kraków 108
Ashburn 76
New York 72
Dublin 61
Milan 60
Jakarta 42
Jacksonville 40
Redmond 36
San Mateo 36
Boston 27
Rome 27
Wilmington 26
Princeton 24
Ann Arbor 23
Beijing 22
Marseille 22
Paris 22
Cattolica 21
Helsinki 20
London 19
Moscow 19
Nanjing 19
Pune 17
Redwood City 17
Dearborn 16
Houston 15
Catania 14
Madrid 13
Brussels 12
Los Angeles 12
Nanchang 10
Fairfield 9
Norwalk 9
Lawrence 8
Ottawa 8
Seattle 8
Woodbridge 8
Bremen 7
Changsha 7
Chicago 7
Cusano Milanino 6
Davao City 6
Hebei 6
Turin 6
Washington 6
Boardman 5
Bucharest 5
La Habra 5
Lancaster 5
Mountain View 5
Shenyang 5
Bologna 4
Edinburgh 4
Florence 4
Frankfurt am Main 4
Fuzhou 4
Hangzhou 4
Hefei 4
Hong Kong 4
Jiaxing 4
Kempton Park 4
Lappeenranta 4
Nürnberg 4
Suyeong-gu 4
Tianjin 4
Toronto 4
Amsterdam 3
Atlanta 3
Aversa 3
Cambridge 3
Georgetown 3
Guadalupe 3
Jinan 3
Kish 3
Kunming 3
Lisbon 3
Longarone 3
Manchester 3
San Francisco 3
Seoul 3
Stockholm 3
Surrey 3
Taipei 3
Warsaw 3
A Coruña 2
Abidjan 2
Andover 2
Angke 2
Ansbach 2
Arcadia 2
Augusta 2
Bangkok 2
Basel 2
Benidorm 2
Bogotá 2
Brno 2
Burnaby 2
Charleston 2
Totale 1.653
Salva come PNG Salva come JPEG
Nome #
The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study 355
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 139
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 137
Cognitive reserve and neuropsychological functioning in older HIV-infected people 102
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 100
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 95
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 92
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 87
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 86
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 86
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 80
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 78
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 78
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 72
Whole-genome sequencing reveals host factors underlying critical COVID-19 70
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 69
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 62
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 61
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 60
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 60
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 57
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 55
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 55
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 54
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 53
An explainable model of host genetic interactions linked to COVID-19 severity 52
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 51
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 51
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 50
Treatment of HCV infection with the novel NS3/4A protease inhibitors 46
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 40
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 37
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 34
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 32
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 32
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 30
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 28
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 25
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 22
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 18
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 15
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 10
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 8
Totale 2.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.784
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020149 0 0 0 0 0 19 16 2 13 3 88 8
2020/2021106 23 11 4 5 12 8 6 2 13 6 12 4
2021/2022269 12 3 4 19 7 12 13 53 10 27 34 75
2022/2023887 96 105 53 116 61 100 32 77 101 70 58 18
2023/2024567 27 108 28 40 36 126 31 25 24 24 39 59
2024/2025352 30 40 91 52 106 33 0 0 0 0 0 0
Totale 2.824